Last reviewed · How we verify
Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder
This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.
Details
| Lead sponsor | Johns Hopkins University |
|---|---|
| Phase | Phase 2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 45 |
| Start date | 2026-07 |
| Completion | 2028-09 |
Conditions
- Alcohol Use Disorder
Interventions
- Placebo
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Naltrexone (oral tablets)
Primary outcomes
- Participant-reported Adverse Events — 14 days
Participant-reported adverse events during the course of the trial
Countries
United States